[ad_1]
Original title: The new version of the medical insurance drug catalog is fully covered by new drugs for coronary pneumonia.
Xinhua Finance, Beijing, March 1 (Reporter Peng Yunjia) The latest version of the National Health Insurance Drug List was officially released on March 1. The adjusted health insurance drug catalog includes 119 drugs and 29 drugs.
The “zombie drugs”, the new anticancer drugs, the drugs related to the treatment of the new coronary pneumonia were eliminated and the average price of the new drugs included was reduced by 50.64% … The latest version of the Medical insurance drug catalog once again reflects the functional positioning of “basic protection” and promotes the realization of medical insurance, companies, Patients “win-win for the three parties.”
New medications for coronary pneumonia are included in health insurance.
Compared to previous years, one of the highlights of this adjustment to the health insurance drug catalog is that the number of drugs negotiated for price cuts is the largest and the treatment fields benefited the most.
119 new drugs were added. These drugs involve a total of 31 clinical groups, among which are chronic obstructive pulmonary drugs, drugs for lupus erythematosus, antidepressant drugs, etc., which represent 86% of all clinical groups. Patients benefit from a wide range of patients and their sense of profit is even stronger.
Newly incorporated drugs related to the treatment of a new coronary pneumonia. All drugs listed in the latest version of the National New Coronary Pneumonia Treatment Plan have been included in the National Health Insurance Drug List. For example, ribavirin injections, Abidol granules, and other medications have been put on the list to respond to new coronary disease. pneumonia epidemic.
17 new anticancer drugs have been added. 17 new cancer drugs have been added to this catalog fit, including good new drugs like PD-1 and lenvatinib. The level of protection for cancer drugs in the catalog has been raised again.
Name 29 types of medications. These “recalled” drugs are primarily of low clinical value and can be replaced, or their registration numbers have been revoked by the department of drug regulation and become “zombie drugs.” In demonstration and review, experts consider substitutability as an important indicator, and drugs that have been transferred out of the catalog have drugs of equivalent or better efficacy that can be substituted. The launch of these drugs will lead to more new and good drugs being added to the catalog.
New drugs “in the group”. In order to meet patients’ needs for newly listed medications, medications that were marketed prior to August 17, 2020 were included in the scope of this catalog adjustment, of which 16 newly listed medications were transferred to the catalog.
It can be seen that the current adjustment of the medical insurance drug catalog includes cost-effective drugs, drugs of low clinical value, and full coverage of new drugs related to coronary pneumonia. The focus continues to be on “basic protection” and improving the availability of medicines. for patients.
The average price of newly included drugs is reduced by 50.64%
The relevant head of the National Medical Insurance Bureau said that the average price of the 119 drugs that were successfully negotiated was reduced by 50.64%. By negotiating price cuts and reimbursing health insurance, the cumulative patient burden is expected to drop by about 28 billion yuan in 2021.
This catalog adjustment is the first time that a price reduction has been negotiated for the “old varieties” in the catalog. Review experts have verified that 14 drugs from the catalog with significantly higher prices or costs are included in the negotiation. Annual sales of these drugs exceed one billion yuan. After negotiation, all 14 drugs were successfully negotiated and kept in the catalog, with an average price reduction of 43.46%.
Compared to the drugs on the new access list, some “old products” have experienced a “backwards” price phenomenon. The renegotiation of “old products” contributes to improving the economy and equity of medicines, and can also effectively reduce the burden on patients and increase the benefits of the use of health insurance funds.
As for the anticancer drugs in the catalog that expired at the end of 2020, the National Medical Insurance Office renewed or renegotiated 14 exclusive drugs according to the regulations, with an average drop of 14.95%, of which individual first-line. cancer drugs were reduced by more than 60%. The price of 14 cancer drugs is estimated to be reduced, which is expected to save more than 3 billion yuan for cancer patients in 2021.
Xiong Xianjun, director of the Medical Services Management Department of the National Health Insurance Administration, said that under the premise of the general security of the controllable health insurance fund, the health insurance fund expenses have not increased significantly and the expenses of Insured patients’ medications have been significantly reduced. and the capacity and level of protection of medical insurance drugs has been improved.
Adjustment of the multiregional health insurance drug catalog
With reference to the latest version of the health insurance drug catalog, documents related to the implementation of the new 2020 version of the national drug catalog have been published successively in many parts of the country, as well as relevant notices for local catalogs of complementary drugs. .
For example, the Beijing Health Insurance Drug Catalog has included all 119 newly added drugs, adjusted and improved the types of outpatient special disease reimbursements, and included many new drugs in the outpatient special disease reimbursements, like the addition of the new drug “Sinimod”. And “Fingolimod” are included in the scope of reimbursement of drugs for special diseases in the “Multiple Sclerosis” clinic.In addition, 19 other new drugs, such as “Zebutinib”, have been included in the scope of drug reimbursement for special diseases such as malignant tumor in Beijing.
In addition to the unified classification management of traded drugs and high-value drugs, Sichuan Province has also included 12 traded drugs such as Degu aspartame and insulin in the scope of diabetes outpatient use in urban and rural residents of the province. .
With the implementation of the new version of the medical insurance drug catalog, the National Medical Insurance Office will also guide designated medical institutions to form links, optimize and update drugs equipped and used by institutions in a timely manner, improve the level of clinical medication, and guide all regions to improve outpatient insurance policies and open designated health insurance pharmacy channels, Reasonably adjust full control and other methods to promote the implementation of drugs in the new version of the catalog.
Massive information, accurate interpretation, all in the Sina Finance APP
